DR SMITA RAMACHANDRAN
Salt and Blood pressure problem in newborns : Let’s understand CAH !
Congenital Adrenal Hyperplasia (CAH) is a genetic condition affecting hormone production in the adrenal...
Type 1 Diabetes Mellitus (T1DM) is an autoimmune condition characterized by immune-mediated destruction of pancreatic beta cells, culminating in lifelong dependence on daily insulin. In recent years, groundbreaking disease-modifying therapies like Teplizumab have emerged, representing the first approved immunotherapy to delay the clinical onset of T1DM.
Teplizumab is a humanized monoclonal antibody targeting the CD3 antigen on autoreactive T-lymphocytes. By deactivating destructive killer T-cells and supporting regulatory T-cells, Teplizumab preserves functional insulin-producing pancreatic beta-cell mass before clinical symptoms begin.
Understanding the preclinical progression of Type 1 Diabetes is essential for identifying therapy candidates:
Presence of ≥2 islet autoantibodies with completely normal blood glucose and normal glucose tolerance.
Presence of ≥2 autoantibodies with impaired fasting glucose or abnormal oral glucose tolerance (OGTT).
Manifestation of hallmark symptoms (polyuria, polydipsia, weight loss) requiring daily exogenous insulin therapy.
Complete or near-complete pancreatic beta cell exhaustion requiring intensive lifelong insulin delivery.
Regulatory approval focuses specifically on Stage 2 Type 1 Diabetes in patients aged 8 years and older who meet both of the following criteria:
Teplizumab is administered as a continuous once-daily intravenous infusion for 14 consecutive days under controlled clinical observation. Daily dosing is incrementally titrated over the first 5 days to mitigate infusion reactions and cytokine release.
The most common clinical adverse reactions observed during the 14-day infusion include:
The advent of disease-modifying immunotherapy highlights the immense power of early screening in high-risk pediatric populations to preserve insulin function and delay diabetes onset.
Consult our specialist for personalised guidance and care.